Study to Evaluate the Safety and Efficacy of CJ-30060 in Hypertensive Patients With Hyperlipidemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

203 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-10-14

Study Completion Date

2017-09-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the safety and efficacy of CJ-30060 compared with amlodipine/valsartan combination therapy and valsartan/rosuvastatin combination therapy in hypertensive patients with hyperlipidemia

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Evaluate the Safety and Efficacy of CJ-30061 in Hypertensive Patients With Hyperlipidemia

NCT03639480

Hypertension Hyperlipidemia

UNKNOWN PHASE3

Clinical Trial of Temisartan/Amlodipine & Rosuvastatin in Subjects With Hypertension and Hyperlipidemia

NCT03067688

Hypertension Hyperlipidemia

COMPLETED PHASE3

Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy

NCT00446563

Hypertension; Hypertrophy, Left Ventricular

COMPLETED PHASE3

Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension

NCT00425373

Essential Hypertension

COMPLETED PHASE2/PHASE3

Pharmacokinetic Drug Interaction Study Following Co-administration of Valsartan, Hydrochlorothiazide and Amlodipine in Patients With Hypertension

NCT00548067

Hypertension

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension With Hyperlipidemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Test

Amlodipine 10mg + Valsartan 160mg + Rosuvastatin 20mg

Group Type EXPERIMENTAL

Amlodipine 10 mg + Valsartan 160 mg + Rosuvastatin 20 mg

Intervention Type DRUG

Reference 1

Amlodipine 10mg + Valsartan 160mg

Group Type ACTIVE_COMPARATOR

Amlodipine 10 mg + Valsartan 160 mg

Intervention Type DRUG

Reference 2

Valsartan 160mg + Rosuvastatin 20mg

Group Type ACTIVE_COMPARATOR

Valsartan 160 mg + Rosuvastatin 20 mg

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Amlodipine 10 mg + Valsartan 160 mg + Rosuvastatin 20 mg

Intervention Type DRUG

Amlodipine 10 mg + Valsartan 160 mg

Intervention Type DRUG

Valsartan 160 mg + Rosuvastatin 20 mg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged between 19 and 74 years
* Patient with dyslipidemia and hypertension

Exclusion Criteria

* At screening, siSBP ≥ 200 mmHg or siDBP ≥ 120mmHg or LDL-C \> 250mg/dL or TG ≥ 400mg/dL
* At screening, siSBP difference is ≥ 20 mmHg or siDBP difference is ≥10 mmHg
* Secodary hypertension
* Type I or uncontrolled diabetes mellitus (HbA1c ≥ 9 %)

Minimum Eligible Age

19 Years

Maximum Eligible Age

74 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No